Hebei Changshan Biochem Pharma (300255) — Net Asset Momentum
Hebei Changshan Biochem Pharma (300255) recorded a net asset momentum of -14.7% as of December 2024, with net assets of CN¥1.54 Billion CNY. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See Hebei Changshan Biochem Pharma (300255) liquidity interval to measure how many days the company can operate on defensive assets alone.
YoY Momentum
Current Net Assets
Years of Data
Country
Hebei Changshan Biochem Pharma Net Asset Momentum (2008–2024)
This chart tracks Hebei Changshan Biochem Pharma's year-over-year net asset growth across 17 annual reporting periods from 2008 to 2024. The most recent momentum reading is -14.7%, with net assets of CN¥1.54 Billion CNY as of December 2024. Read debt load of Hebei Changshan Biochem Pharma for a breakdown of total debt and financial obligations.
Annual Net Asset History for Hebei Changshan Biochem Pharma (2008–2024)
The table below shows the complete annual net asset history for Hebei Changshan Biochem Pharma from 2008 to 2024, covering 17 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see 300255 stock market capitalisation.
| Year | Net Assets (CNY) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2024 | CN¥1.54 Billion | CN¥4.52 Billion | CN¥2.99 Billion | ▼ -14.7% |
| 2023 | CN¥1.80 Billion | CN¥4.60 Billion | CN¥2.80 Billion | ▼ -41.1% |
| 2022 | CN¥3.05 Billion | CN¥6.04 Billion | CN¥2.98 Billion | ▼ -0.6% |
| 2021 | CN¥3.07 Billion | CN¥5.19 Billion | CN¥2.12 Billion | ▲ +7.7% |
| 2020 | CN¥2.85 Billion | CN¥4.57 Billion | CN¥1.72 Billion | ▲ +4.8% |
| 2019 | CN¥2.72 Billion | CN¥3.94 Billion | CN¥1.22 Billion | ▲ +7.9% |
| 2018 | CN¥2.52 Billion | CN¥3.84 Billion | CN¥1.32 Billion | ▲ +3.6% |
| 2017 | CN¥2.44 Billion | CN¥3.53 Billion | CN¥1.09 Billion | ▲ +6.4% |
| 2016 | CN¥2.29 Billion | CN¥3.13 Billion | CN¥842.59 Million | ▲ +45.7% |
| 2015 | CN¥1.57 Billion | CN¥2.33 Billion | CN¥757.07 Million | ▲ +10.1% |
| 2014 | CN¥1.43 Billion | CN¥2.04 Billion | CN¥617.87 Million | ▲ +11.0% |
| 2013 | CN¥1.29 Billion | CN¥1.65 Billion | CN¥359.78 Million | ▲ +14.2% |
| 2012 | CN¥1.13 Billion | CN¥1.42 Billion | CN¥292.77 Million | ▲ +14.0% |
| 2011 | CN¥987.45 Million | CN¥1.19 Billion | CN¥198.78 Million | ▲ +350.1% |
| 2010 | CN¥219.39 Million | CN¥430.64 Million | CN¥211.25 Million | ▲ +37.8% |
| 2009 | CN¥159.19 Million | CN¥266.35 Million | CN¥107.15 Million | ▲ +70.4% |
| 2008 | CN¥93.43 Million | CN¥196.59 Million | CN¥103.16 Million | — |